<!DOCTYPE html>
<html lang="pt-br">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>Referências Fisioterapia na AME</title>
  <style type="text/css">
    * {
      box-sizing: border-box;
      font-family: Arial, Helvetica, sans-serif;
      padding: 0;
      margin: 0;
    }
    body {
      padding: 20px;
    }
    h1 {
      font-weight: bold;
      margin-bottom: 30px;
    }
    ol {
      list-style: none;
    }
    li {
      font-size: 1.2rem;
      margin-bottom: 15px;
    }
  </style>
</head>
<body>
  <h1>Referências:</h1>
  <ol start="1">
    <li>
      1. GRANADO, L. N. et al. Prevalência de sintomas depressivos em adolescentes agressores e vítimas de bullying. Brazilian Journal of Health Review, Curitiba, v. 4, n. 2, p. 6027-6049, 2021.
    </li>
    <li>
      2. Clabor N., et al. (2019). Nusinersen: A Treatment for Spinal Muscular Atrophy. Annals of Pharmacotherapy, 53(1), 61–69.
    </li>
    <li>
      3. Cure E, Cure MC. Comment on “Hearing loss and COVID-19: A note”. American Journal of Otolaryngology. 2020 Jul;41(4):102513.
    </li>
    <li>
      4. Pane M., et al., Nusinersen in type 1 SMA infants, children and young adults: Preliminary results on motor function, Neuromuscular Disorders (2018), https://doi.org/10.1016/j.nmd.2018.05.010
    </li>
    <li>
      5. Prior T.W. Sínal muscular atrophy: a time for screening. Current Opinion in Pediatrics.2010;22:696-702.
    </li>
    <li>
      6. FINKEL RS, et al. Diagnosis and management of spinal muscular atrophy: Part 2: Pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics. Neuromuscular Disorders, 2018; 28(3): 197-207.
    </li>
    <li>
      7. Mercuri, E.; Finkel, R.S.; Muntoni, F.; et al.(2018). Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedicand nutritional care. Neuromuscular Disorders. 28(2), 103 -115,2018.
    </li>
    <li>
      8. Wells GA, Shea B, O’Connell Da, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses [Internet]. Oxford: The Ottawa Hospital Research Institute; 2000. [cited 2021 Aug 04].
    </li>
    <li>
      9. Finkel RS, Mercuri E, Darras BT, Connolly AM, Kuntz NL, Kirschner J, et al.; ENDEAR Study Group. Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy. N Engl J Med 2017 2;377:1723-1732. PMID: 29091570
    </li>
    <li>
      10. Salem, Y. and S.J. Gropack, Aquatic Therapy for a Child with Type III Spinal Muscular Atrophy: A Case Report. 2010.
    </li>
    <li>
      11. Yagcioglu, GA,. et al. Long-Term Effects of Nusinersen Combined Physiotherapy in Spinal Muscular Atrophy Type 1: A Case Study (2022, p. 96). DOI:
    </li>
    <li>
      12. Soares, J.A.; et al.(2006). Fisioterapia e qualidade de vida de paciente com amiotrofia espinal progressiva tipo I –Relato de Caso. Arq Ciência e Saúde. 13(1),.44-7.
    </li>
    <li>
      13. Morrow, T. (2017). New Therapy for Spinal Muscular Atrophy Offers Modest Bang for Pharmaceutical Buck. Tomorrow’s Medicine. Managed Care, 26(2), 36-37, 2017.
    </li>
    <li>
      14. Souza, C.P.V.; et al.(2019). Pico de fluxo de tosse em crianças e jovens com atrofia muscular espinhal tipo II e tipo III. Fisioter Pesqui. 25(4), 432-437.
    </li>
    <li>
      15. Ferreira, R.D.D.; & Lucato,J.J. (2021). A atuação da fisioterapia nas repercussões motoras e respiratórias dos pacientes com atrofia muscular espinhal tipo I. Rev Pediatr. 11(3), 220.
    </li>
    <li>
      16. Marin, M. S.; & Castro, R. F. S. (2020). Percepção do uso Spinoza associado à fisioterapia em indivíduos com atrofia muscular espinhal. [monografia] UniCesumar. Maringá-PR, 2020.
    </li>
    <li>
      17. Costa, J.O., et al. Genes de sobrevivência do neurônio motor e a atrofia muscular espinhal 5q. Genética na Escola, v 43, n 2, 2021.
    </li>
  </ol>
  
</body>
</html>